A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

NCT04059094 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Not due to safety reasons

Conditions

Cystic Fibrosis

Interventions

DRUG: BI 1265162
DRUG: Placebo

Sponsor

Boehringer Ingelheim